Fortis Hospital Manesar Opens Dedicated Cancer Institute

Fortis Healthcare has announced the opening of a dedicated cancer treatment facility at its Manesar location in Haryana, India. The Fortis Cancer Institute represents the hospital's attempt to consolidate oncology services under one integrated platform, according to a press release distributed through Business Standard on April 27, 2026.

The facility brings together several advanced treatment technologies that have become standard in tier-one cancer centers globally. The infrastructure includes a Da Vinci Xi robotic surgery system, which allows surgeons to operate through small incisions using wristed instruments that move with greater range than the human hand. For abdominal cancers, the institute offers HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) — procedures that deliver heated chemotherapy directly to the abdominal cavity rather than through systemic IV infusion.

These aren't just marketing terms. Patients undergoing HIPEC experience a two-to-three-hour procedure where surgeons circulate heated chemotherapy solution through the abdomen while monitoring temperature and drug concentration in real time. The physical reality involves significant recovery time, but the targeted approach can reduce systemic side effects compared to traditional chemotherapy.

The institute also features HAIP (Hepatic Artery Infusion Pump) chemotherapy for liver cancers, fluorescence-guided breast surgery, oncoplastic breast surgery, and a dedicated lymphedema clinic. Organ-specific oncology programmes are designed to deliver personalized treatment rather than one-size-fits-all protocols.

Precision oncology forms the backbone of the institute's approach. A multi-disciplinary tumor board reviews cases, integrating molecular diagnostics, targeted therapies, immunotherapy, and genetic counseling. Dr. Vinay Samuel Gaikwad, Senior Director of Surgical Oncology at the facility, stated that the focus is on using advanced technologies to make treatment more targeted and less invasive. Dr. Pooja Babbar, Consultant Medical Oncology, emphasized that modern cancer care requires collaborative decision-making rather than single-treatment approaches.

What this actually means for patients in the Manesar region is access to technologies that previously required travel to Delhi or other major medical hubs. The geographic advantage is real — Manesar sits in the National Capital Region, serving a population where cancer cases are rising globally. Abhijit Singh, Facility Director at Fortis Hospital Manesar, noted the critical gap in accessible, high-quality treatment that the institute aims to bridge.

However, readers should note the source nature. The Business Standard article carries an explicit disclaimer: "No Business Standard Journalist was involved in creation of this content." This is a paid press release distributed through NewsVoir, not independent journalism. The information comes directly from Fortis Healthcare itself, which operates 36 healthcare facilities across 12 states with over 6,000 operational beds.

The timing aligns with broader industry trends. Fortis is simultaneously organizing the Fortis Cancer Summit 2026, scheduled for May 1-3, 2026, which will cover AI integration in oncology, CAR-T therapies, and precision medicine. The summit's theme — "Beyond Evidence-Based Oncology" — suggests the company is positioning itself at the intersection of traditional medicine and emerging technologies.

Whether this translates to better patient outcomes remains to be seen. Technology alone doesn't guarantee results. The real test involves clinical outcomes, patient wait times, cost accessibility, and whether the promised precision oncology actually reaches patients beyond the marketing materials. (The gap between press release promises and actual patient experience is often where healthcare stories get complicated.)

For context, robotic surgery systems like Da Vinci Xi cost between $1.5 to $2.5 million upfront, plus annual maintenance fees of $150,000 to $200,000. These costs inevitably factor into patient billing. The question isn't whether the technology exists — it does. The question is whether patients can access it affordably.

The institute's emphasis on molecular oncology and genetic testing is noteworthy. These approaches require specialized laboratory infrastructure and trained personnel to interpret results. Not all hospitals claiming "precision oncology" have the actual capability to run comprehensive genomic profiling on patient samples.

Fortis Healthcare's network spans multiple states, but the Manesar location represents a specific regional investment. The facility director's statement about bringing world-class care closer to patients reflects a genuine need — cancer treatment delays can significantly impact survival rates, and geographic barriers remain a real problem in India's healthcare landscape.

What's missing from the announcement are concrete details about pricing, insurance coverage, expected patient capacity, and wait times. These are the metrics that matter most to patients navigating cancer treatment decisions. Technology specifications are easy to list; operational realities are harder to quantify.

The launch also comes as India's healthcare sector faces increasing scrutiny over treatment costs and outcomes. Private hospital expansions like this one must balance commercial viability with public health needs. Whether users actually pay for it remains the real question.

For now, the Fortis Cancer Institute at Manesar represents another data point in India's evolving oncology landscape. The technologies are legitimate. The infrastructure appears substantial. The regional need is documented. The execution — that's what will determine whether this becomes a meaningful advancement or another example of healthcare marketing outpacing delivery.

Artūras Malašauskas is an AI Systems Integrator with 20+ years of production-grade web engineering experience. He has designed, shipped, and scaled enterprise Python/PHP systems for logistics, SaaS, and public-sector clients. For the past year, he has focused exclusively on AI integrations: deploying open-source LLMs, building generative media pipelines (image, audio, video), and engineering multi-agent workflows for real production environments. His standard: reproducibility, security, cost-efficient inference—no vaporware. He documents and evaluates emerging AI tooling, separating verified capabilities from marketing noise. Technical editor at: muza-ai.eu, ai-verslas.lt, ai-naujinos.lt Connect on LinkedIn